

What is claimed is:

1. A method of conferring donor CDR binding affinity onto an antibody acceptor variable region framework, comprising:

5 (a) constructing a population of altered antibody variable region encoding nucleic acids, said population comprising encoding nucleic acids for an acceptor variable region framework containing a plurality of different amino acids at one or more acceptor
10 framework region amino acid positions and donor CDRs containing a plurality of different amino acids at one or more donor CDR amino acid positions;

(b) expressing said population of altered variable region encoding nucleic acids, and

15 (c) identifying one or more altered variable regions having binding affinity substantially the same or greater than the donor CDR variable region. ?

2. The method of claim 1, wherein said one or more altered variable regions are identified by comparing
20 the relative binding of said altered variable regions to said donor CDR variable region.

3. The method of claim 1, wherein said one or more altered variable regions are identified by measuring the binding affinity of said altered variable regions.

25 4. The method of claim 1, wherein said one or more altered variable regions are identified by measuring the association rate (k_{on}) or disassociation rate (k_{off}) of said altered variable regions.

5 ~~6~~ ⁶⁴ 67

6. The method of claim 1, wherein said acceptor variable region framework is a light chain variable region framework.

67. The method of claim 1, wherein said framework amino acid positions are located in framework region 1, framework region 2, framework region 3 or framework region 4.

78. The method of claim 1, wherein said donor CDR amino acid positions is located in CDR1, CDR2 or CDR3.

89. The method of claim 1, wherein said one or more amino acid positions in said acceptor framework region is selected by differences in amino acid identity between corresponding positions in donor and acceptor framework regions.

910. The method of claim 1, wherein said one or more amino acid positions in said acceptor framework region is selected as being a canonical framework residue.

1011. The method of claim 1, wherein said one or more amino acid positions in said acceptor framework region is selected as being exposed to solvent.

1112. The method of claim 1, wherein said one or more amino acid positions in said acceptor framework region is selected by a characteristic within the group consisting of being proximal to a CDR, predicted to contact the opposite domain in the V_L - V_H interface, lack of relatedness to the donor framework amino acid position at that position and predicted to modulate CDR activity.

Official Action

Claim 2
8-11

Rule 1.126

~~12~~ 13. The method of claim 1, wherein said one or more amino acid positions in said donor CDR is selected as being a CDR residue as defined by Kabat.

13-14. The method of claim 5, wherein said
5 altered variable regions are coexpressed with a light
chain variable region.

~~11/4/15~~ 15. The method of claim 6, wherein said altered variable region is coexpressed with a heavy chain variable region.

10 ~~15-16~~. A method of simultaneously grafting and
optimizing the binding affinity of a variable region
binding fragment, comprising:

(a) constructing a population of altered heavy chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework region and CDR amino acid positions;

(b) constructing a population of altered light chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework regions and CDR amino acid positions;

(c) coexpressing said populations of heavy and light chain variable region encoding nucleic acids to produce diverse combinations of heteromeric variable region binding fragments, and

(d) identifying one or more heteromeric variable region binding fragments having affinity substantially the same or greater than the donor CDR heteromeric variable region binding fragment.

	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

~~16~~ 17. The method of claim ~~16~~, wherein said one or more heteromeric variable region binding fragments are identified by comparing the relative binding of said heteromeric variable region binding fragments to said donor CDR heteromeric variable region binding fragment.

~~17-18~~ The method of claim ~~16~~ wherein said one or more heteromeric variable region binding fragments are identified by measuring the binding affinity of said heteromeric variable region binding fragments.

10 ~~18~~ 19. The method of claim 16, wherein said one or more heteromeric variable region binding fragments are identified by measuring the association rate (k_{on}) or disassociation rate (k_{off}) of said heteromeric variable region binding fragments.

15 ~~19 20~~. The method of claim ~~16~~, wherein said
framework amino acid positions are located in framework
region 1, framework region 2, framework region 3 or
framework region 4.

~~21.~~ The method of claim ~~16~~¹⁵, wherein said donor
20 CDR amino acid positions is located in CDR1, CDR2 or
CDR3.

~~21~~ 22. The method of claim ~~16~~¹⁵, wherein said one or more amino acid positions in said acceptor framework region is selected by differences in amino acid identity between corresponding positions in donor and acceptor framework regions.

70

~~67~~

15

~~23~~ 23. The method of claim ~~16~~, wherein said one or more amino acid positions in said acceptor framework region is selected as being a canonical framework residue.

5 ~~23~~ 24. The method of claim ~~16~~, wherein said one or more amino acid positions in said acceptor framework region is selected as being exposed to solvent.

10 ~~24~~ 25. The method of claim ~~16~~, wherein said one or more amino acid positions in said acceptor framework region is selected by a characteristic within the group consisting of being proximal to a CDR, predicted to contact the opposite domain in the V_L - V_H interface, lack of relatedness to the donor framework amino acid position at that position and predicted to modulate CDR activity.

15 ~~25~~ 26. The method of claim ~~16~~, wherein said one or more amino acid positions in said donor CDR is selected as being a CDR residue as defined by Kabat.

20 ~~26~~ 27. A method of optimizing the binding affinity of an antibody variable region, comprising:
(a) constructing a population of antibody variable region encoding nucleic acids from a parent variable region encoding nucleic acid, said population comprising two or more CDRs containing a plurality of different amino acids at one or more CDR amino acid
25 positions;
(b) expressing said population of variable region encoding nucleic acids, and
(c) identifying one or more variable regions having binding affinity substantially the same or greater
30 than the parent variable region.

ORIGINAL SUBMITTED

RLK 1.12.6

71

28

26

~~28~~ The method of claim ~~27~~, wherein said one or more variable regions are identified by comparing the relative binding of said variable regions to said parent variable region.

5

~~29~~

26

The method of claim ~~27~~, wherein said one or more variable regions are identified by measuring the binding affinity of said variable regions.

10

~~30~~

26

The method of claim ~~27~~, wherein said one or more variable regions are identified by measuring the association rate (kon) or disassociation rate (koff) of said variable regions.

~~31~~

26

The method of claim ~~27~~, wherein said variable region is a heavy chain variable region.

~~32~~

26

15

The method of claim ~~27~~, wherein said variable region is a light chain variable region.

~~33~~

26

The method of claim ~~27~~, wherein said two or more CDRs are selected from the group consisting of CDR1, CDR2 or CDR3.

~~34~~

26

20

The method of claim ~~27~~, wherein said one or more amino acid positions in said two or more CDRs is selected as being a CDR residue as defined by Kabat.

~~35~~

26

The method of claim ~~27~~, wherein said variable regions are coexpressed with a light chain variable region.

25

~~36~~

31

The method of claim ~~32~~, wherein said variable regions are coexpressed with a heavy chain variable region.

Official Gazette

RLK 1/26

72
~~59~~

26

~~36~~ 37. The method of claim ~~27~~, wherein said antibody variable region is selected from the group consisting of native, grafted, altered and optimized variable regions.

5 ~~31~~ 38. A method of optimizing the activity of a catalytic antibody variable region, comprising:

(a) constructing a population of heavy chain variable region encoding nucleic acids from a parent heavy chain variable region encoding nucleic acid, said
10 population comprising two or more CDRs containing a plurality of different amino acids at one or more CDR amino acid positions;

(b) constructing a population of light chain variable region encoding nucleic acids from a parent
15 light chain variable region encoding nucleic acid, said population comprising two or more CDRs containing a plurality of different amino acids at one or more CDR amino acid positions;

(c) coexpressing said population of heavy and
20 light chain variable region encoding nucleic acids containing said two or more CDRs having said plurality of different amino acids at one or more CDR positions to produce diverse combinations of heteromeric variable region catalytic fragments, and

25 (d) identifying one or more heteromeric variable regions having optimized catalytic activity compared to said parent catalytic antibody variable region.

~~36~~ 39. The method of claim ~~38~~, wherein said one
30 or more heteromeric variable regions are identified by comparing the relative catalytic activity of said heteromeric variable regions to said parent variable region.

ORIGINAL

REV 1.126

73

37

340. The method of claim 38, wherein said one or more heteromeric variable regions are identified by measuring a substrate association rate (k_{on}), a substrate disassociation rate (k_{off}), substrate binding affinity, a transition state binding affinity, a turnover rate or a K_m .

RULE 1.126

4041. The method of claim 38, wherein said two or more CDRs are selected from the group consisting of CDR1, CDR2 and CDR3.

37

10 4142. The method of claim 38, wherein said one or more amino acid positions in said two or more CDRs is selected as being a CDR residue as defined by Kabat.

37

CONFIDENTIAL

add
YB3
mod
C3